Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs

被引：422

作者：

Chen, Chenglong ^{[1
,2
]}

Xie, Lu ^{[1
]}

Ren, Tingting ^{[1
,2
]}

Huang, Yi ^{[1
,2
]}

Xu, Jie ^{[1
]}

Guo, Wei ^{[1
,2
]}

机构：

[1] Peking Univ, Musculoskeletal Tumor Ctr, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China

[2] Beijing Key Lab Musculoskeletal Tumor, Beijing, Peoples R China

来源：

CANCER LETTERS | 2021年 / 500卷

基金：

中国国家自然科学基金;

关键词：

Osteosarcoma; Cancer immunotherapy; PD-1; PD-L1; Tumor immune microenvironment; MODIFIED T-CELLS; PHASE-I TRIAL; DENDRITIC CELLS; FUNCTIONAL-ANALYSIS; ANTI-HER2; ANTIBODY; ANTITUMOR IMMUNITY; TUMOR PROGRESSION; PD-L1; EXPRESSION; LUNG METASTASIS; BREAST-CANCER;

D O I：

10.1016/j.canlet.2020.12.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Osteosarcoma (OS) is the most common primary malignancy of the bone and has a high propensity for local invasion and metastasis. Although combining surgery with chemotherapy has immensely improved the outcomes of osteosarcoma patients, the prognosis of metastatic or recurrent osteosarcomas is still unsatisfactory. Immunotherapy has proven to be a promising therapeutic strategy against human malignancies and improved understanding of the immune response to OS, and biomarker development has increased the number of patients who benefit from immunotherapies in recent years. Here, we review recent advances in immunotherapy in osteosarcoma and discuss the mechanisms and status of immunotherapies in both preclinical and clinical trials as well as future therapies on the horizon. These advances may pave the way for novel treatments requisite for patients with osteosarcoma in need of new therapies.

引用

页码：1 / 10

页数：10

共 158 条

[1] Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].

Ahmed, Nabil ;

Brawley, Vita S. ;

Hegde, Meenakshi ;

Robertson, Catherine ;

Ghazi, Alexia ;

Gerken, Claudia ;

Liu, Enli ;

Dakhova, Olga ;

Ashoori, Aidin ;

Corder, Amanda ;

Gray, Tara ;

Wu, Meng-Fen ;

Liu, Hao ;

Hicks, John ;

Rainusso, Nino ;

Dotti, Gianpietro ;

Mei, Zhuyong ;

Grilley, Bambi ;

Gee, Adrian ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Wels, Winfried S. ;

Wang, Lisa L. ;

Anderson, Peter ;

Gottschalk, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+

[2] Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression [J].

Ahmed, Nabil ;

Salsman, Vita S. ;

Yvon, Eric ;

Louis, Chrystal U. ;

Perlaky, Laszlo ;

Wels, Winfried S. ;

Dishop, Meghan K. ;

Kleinerman, Eugenie E. ;

Pule, Martin ;

Rooney, Cliona M. ;

Heslop, Helen E. ;

Gottschalk, Stephen .

MOLECULAR THERAPY, 2009, 17 (10) :1779-1787

[3] Bone microenvironment signals in osteosarcoma development [J].

Alfranca, Arantzazu ;

Martinez-Cruzado, Lucia ;

Tornin, Juan ;

Abarrategi, Ander ;

Amaral, Teresa ;

de Alava, Enrique ;

Menendez, Pablo ;

Garcia-Castro, Javier ;

Rodriguez, Rene .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (16) :3097-3113

[4] Unusual abdominal metastases in osteosarcoma [J].

Berhe, Simon ;

Danzer, Enrico ;

Meyers, Paul A. ;

Behr, Gerald ;

LaQuaglia, Michael P. ;

Price, Anita P. .

JOURNAL OF PEDIATRIC SURGERY CASE REPORTS, 2018, 28 :13-16

[5] Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].

Bettelli, E ;

Carrier, YJ ;

Gao, WD ;

Korn, T ;

Strom, TB ;

Oukka, M ;

Weiner, HL ;

Kuchroo, VK .

NATURE, 2006, 441 (7090) :235-238

[6] CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [J].

Brentjens, Renier J. ;

Davila, Marco L. ;

Riviere, Isabelle ;

Park, Jae ;

Wang, Xiuyan ;

Cowell, Lindsay G. ;

Bartido, Shirley ;

Stefanski, Jolanta ;

Taylor, Clare ;

Olszewska, Malgorzata ;

Borquez-Ojeda, Oriana ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Bernal, Yvette ;

Rijo, Ivelise V. ;

Hedvat, Cyrus ;

Kobos, Rachel ;

Curran, Kevin ;

Steinherz, Peter ;

Jurcic, Joseph ;

Rosenblat, Todd ;

Maslak, Peter ;

Frattini, Mark ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)

[7] Cancer stem cells in osteosarcoma [J].

Brown, Hannah K. ;

Tellez-Gabriel, Marta ;

Heymann, Dominique .

CANCER LETTERS, 2017, 386 :189-195

[8] Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents [J].

Buddingh, Emilie P. ;

Kuijjer, Marieke L. ;

Duim, Ronald A. J. ;

Buerger, Horst ;

Agelopoulos, Konstantin ;

Myklebost, Ola ;

Serra, Massimo ;

Mertens, Fredrik ;

Hogendoorn, Pancras C. W. ;

Lankester, Arjan C. ;

Cleton-Jansen, Anne-Marie .

CLINICAL CANCER RESEARCH, 2011, 17 (08) :2110-2119

[9] Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells [J].

Buddingh, Emilie P. ;

Schilham, Marco W. ;

Eriaty, S. ;

Ruslan, N. ;

Berghuis, Dagmar ;

Szuhai, Karoly ;

Suurmond, Jolien ;

Taminiau, Antonie H. M. ;

Gelderblom, Hans ;

Egeler, R. Maarten ;

Serra, Massimo ;

Hogendoorn, Pancras C. W. ;

Lankester, Arjan C. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (04) :575-586

[10] Immunotherapeutic Approaches to Sarcoma [J].

Burgess, Melissa ;

Tawbi, Hussein .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (06)

← 1 2 3 4 5 6 7 8 9 10 →